Gamma-aminobutyric acid type A receptor benzodiazepine site (GABA_A receptor BZD site) (GABA_A receptor BZD site)

The Gamma-aminobutyric acid type A (GABA_A) receptor benzodiazepine site is a high-affinity allosteric modulatory site located at the interface of the alpha (α1, α2, α3, or α5) and gamma (γ2) subunits of the pentameric GABA_A receptor complex [1, 2]. As the primary inhibitory neurotransmitter receptor in the central nervous system, the GABA_A receptor regulates neuronal excitability by conducting chloride ions into the cell, leading to membrane hyperpolarization [2, 6]. Binding of benzodiazepines or related ligands to this specific site does not activate the receptor directly but instead enhances the receptor's affinity for GABA, thereby increasing the frequency of chloride channel opening [1, 5]. This modulation is critical for managing conditions such as generalized anxiety disorder, insomnia, and epilepsy, where enhancing inhibitory tone is therapeutically beneficial [6, 10]. However, the site is also associated with significant clinical challenges, including the development of pharmacological tolerance, physical dependence, and potential for misuse [11, 12]. Modern drug discovery efforts often target specific alpha-subunit isoforms at this site to decouple desired effects, like anxiolysis, from adverse effects like sedation and amnesia [10, 13].

Other names

Benzodiazepine receptorBZD siteGABA-A receptor modulatory siteOmega receptorBZ siteBenzodiazepine binding site

Positive allosteric modulation (PAM) of GABA-induced chloride currents; Antagonism; Negative allosteric modulation (NAM)